Navigation Links
Cell transplantation and diabetes: New sites, new devices
Date:1/21/2009

Tampa, Fla. (Jan. 21, 2009) Early attempts at islet cell transplantation to treat diabetes date to the nineteenth century, decades before the discovery of insulin in the 1930s. In recent years, research has focused on the anatomical sites best suited for hosting transplanted islet cells. Experimental sites have included the spleen, liver, peritoneal cavity, omentum, subcutaneous tissues and gastric submucosa. However, many transplant attempts at a variety of anatomical sites have failed because of a variety of complications.

While transplanting islet cells into the liver is current practice, improvements in biomedical devices have improved the overall success rates of islet transplantation. Recent advances in islet transplantation are discussed in the January issue of Cell Transplantation (Vol. 17 No.9).

Which anatomical sites are best for islet transplantation?

A review evaluating both anatomical site choice for islet cell transplantation and an ideal source of islet cells was the focus of a report by Dr. Dirk Van der Windt and colleagues at the Thomas E. Starzl Transplantation Institute at the University of Pittsburgh Medical Center. They concluded that transplantation into the liver "may not provide the conditions favoring optimum islet survival."

"Islet transplantation into the portal vein is current clinical practice," said Van der Windt. "However, this site has several characteristics that can hamper islet engraftment and survival."

According to Van der Windt, low oxygen tension and immune and inflammatory responses are among factors that can account for islet cell loss soon after transplantation. Thus, alternative anatomical sites for islet transplantation, sites offering maximum engraftment potential, the efficacious use of insulin and patient safety, are needed.

"The most physiological - and therefore perhaps most supportive, microenvironment for islets - is the pancreas itself," said Van der Windt and co-authors.

They also speculate on the value of porcine islet cells for transplantation, suggesting that these cells offer greater opportunities for selecting a donor at an age when the islets have favorable properties, when islet-like cell clusters isolated from fetal or neonatal piglets retain the ability to mature and proliferate. In addition, these cells are believed to be less immunogenic than adult islet cells and more resistant to hypoxia.

Van der Windt and colleagues suggest that porcine islet cells can provide an unlimited source of islets and in quantities that may satisfy the metabolic requirements of diabetic patients. Too, they are able to produce insulin that both functions in humans and offers opportunities for genetic modification that may help overcome some of the unfavorable site-specific conditions.

"These types of islets may have a better survival potential at different recipient sites," added Van der Windt.

Contact: Dr. Dirk Van der Windt, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, vanderwindtd@upmc.edu,

Engineering a bioartificial pancreas

Another review by Dr. Cherie Stabler and colleagues from the Diabetes Research Institute and the Department of Biomedical Engineering at the University of Miami (Florida), evaluated the engineering of bio-hybrid devices and encapsulation technologies that may aid in the success of islet transplants. According to the researchers, the transplantation of islet cells into the portal vein of the liver has presented several challenges. Overcoming those challenges means recognizing important issues such as vascularization, mechanical protection, device design, biomaterial selection and quality control in device engineering.

"A recent focus has been to redesign bio-hybrid devices that promote vascularization and effective nutrient delivery to prevent islet cell necrosis and at the same time minimize device volumes," said Stabler.

According to Stabler, one bio-hybrid design has been fabricated for pre-vascularization to afford maximum nutrient delivery and minimal exposure to inflammatory agents. At the same time, macrodevices, such as hollow fibers, have also been used for cell loading.

"The combination of these two treatments increased vascularization and blood flow around the bioartificial pancreas when compared to control implants," noted Stabler.

Encapsulation is also a technique for minimizing both immune response and the need for high dose immunosuppressive protocols. By coating the surface of the cell with semi-permeable biomaterial, the ability of host cells to recognize surface antigens on implanted cells is impaired and provides a barrier between the host and transplanted cells. Masking immune recognition also opens the possibility for xenotransplantation.

"Biomaterials used for encapsulation should be well-characterized, pharmaceutical grade and verified as pyrogen and endotoxin-free," explained Stabler. "It is critical to establish guidelines for generating capsules optimized for biocompatibility, immunoprotection and islet function."

Researchers supported the use of the portal vein as a site for islet transplantation, but noted that there are issues with injecting encapsulated cells into the liver. Finally, the research team suggested decreasing capsule size to nano-scale and combining PEGylation coating of capsules with a layer of poly(ethylene) glycol molecules with low-dose immunosuppression to improve engraftment and long-term function.

Contact: Dr. Cherie Stabler, Department of Biomedical Engineering, Director, Tissue Engineering and Nanotechnlogy Laboratory, Diabetes Research Institute, University of Miami, 1450 NW 10th Ave., Miami, FL. 33136. cstabler@med.miami.edu

"These articles published in the current issue of Cell Transplantation offer an unique overview on some of the most promising front line research in islet transplantation: the identification of new sites for transplant and of new approaches for the bioengineering of pancreatic islets," said Dr. Federico Bertuzzi, head of the Islet Transplant Program at the Unit di Diabetologia, Ospedale Niguarda in Milan, Italy and a Cell Transplantation editorial board member. "Taken together, these exciting new strategies demonstrated that two main problems of islet transplantation, poor engraftment and immune recognition, can now be better prevented than in the past. Accordingly, islet transplantation appears a feasible therapeutical option for type 1 diabetes mellitus."


'/>"/>

Contact: Dirk Van der Windt
vanderwindtd@upmc.edu
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related medicine news :

1. American Society of Transplantations Past President Testifies Before Congress at Forum on Organ Donation
2. Patients over age 60 do well after liver transplantation
3. No racial differences seen in outcomes after liver transplantation
4. Predicting survival after liver transplantation
5. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
6. Optimal systemic and splanchnic hemodynamic state after living-donor liver transplantation
7. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
8. American Society of Transplantation Applauds Rep. Inslee for His Efforts to Pass the Charlie W. Norwood Living Organ Donation Act
9. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
10. Extreme obesity affects chances of kidney transplantation
11. Former substance abusers rarely relapse after organ transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: